Achieve Life Sciences, Inc.
NASDAQ:ACHV · NASDAQ Capital Market
-$0.38 today
Vol 4.48M · Avg 1.44M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $28.1M |
| Short-term Investments | $1.2M |
| Other Current | $1.8M |
| Total Current Assets | $31.1M |
| PP&E (Net) | $49.0K |
| Goodwill | $1.0M |
| Intangible Assets | $696.0K |
| Long-term Investments | $235.0K |
| Other Non-current | $30.0K |
| Total Non-current Assets | $2.0M |
| Total Assets | $33.1M |
Analysis
Selected assets total $33.1M for Latest. The largest visible component is Cash & Equivalents at $28.1M, about 84.8% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.9M +64.4% | $12.7M -18.1% | $15.5M -37.1% | $24.7M -42.5% | $43.0M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $15.5M -28.4% | $21.6M | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $0 | $0 -100.0% | $111.0K +5.7% | $105.0K -31.4% | $153.0K | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $3.5M +63.8% | $2.1M +60.5% | $1.3M -47.1% | $2.5M | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $39.9M +9.4% | $36.5M +114.7% | $17.0M -37.9% | $27.3M -38.7% | $44.6M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $64.0K -46.2% | $119.0K +50.6% | $79.0K -35.8% | $123.0K +92.2% | $64.0K | $1.2B | $1.5B | $687.8M |
| Goodwill | $1.0M +0.0% | $1.0M +0.0% | $1.0M +0.0% | $1.0M +0.0% | $1.0M | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $751.0K -22.9% | $974.0K -18.6% | $1.2M -15.6% | $1.4M -13.6% | $1.6M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $20.0K | $0 -100.0% | $50.0K | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $283.0K | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | -$251.0K -743.6% | $39.0K +34.5% | $29.0K -56.1% | $66.0K -63.9% | $183.0K | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $1.9M -12.2% | $2.2M -9.3% | $2.4M -9.5% | $2.6M -9.6% | $2.9M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $41.8M +8.2% | $38.6M +99.4% | $19.4M -35.4% | $30.0M -36.9% | $47.5M | $13.3B | $11.9B | $10.6B |
| Account Payables | $867.0K -55.5% | $1.9M +215.5% | $618.0K -62.8% | $1.7M +97.4% | $841.0K | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $3.8M | $0 -100.0% | $16.7M +3.7% | $16.1M | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $2.5M -16.5% | $3.0M +6.6% | $2.8M +69.2% | $1.7M -13.5% | $1.9M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $9.1M +35.9% | $6.7M -67.9% | $20.8M -3.6% | $21.6M +374.7% | $4.5M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $11.2M +13.8% | $9.8M | $0 | $0 -100.0% | $14.9M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 -100.0% | $1.1M | $0 | $0 | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $11.2M +1.2% | $11.1M +184100.0% | $6.0K -91.3% | $69.0K -99.5% | $14.9M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $20.3M +14.3% | $17.7M -14.8% | $20.8M -3.9% | $21.7M +11.3% | $19.5M | $14.7B | $3.7B | $9.6B |
| Common Stock | $121.0K +17.5% | $103.0K +14.4% | $90.0K +3.4% | $87.0K +10.1% | $79.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$260.2M -26.6% | -$205.6M -24.0% | -$165.8M -21.9% | -$135.9M -45.3% | -$93.6M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $10.0K -67.7% | $31.0K +675.0% | $4.0K +0.0% | $4.0K +0.0% | $4.0K | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $21.5M +3.0% | $20.9M +1543.3% | -$1.4M -117.4% | $8.3M -70.4% | $28.0M | $9.1B | $7.7B | $3.3B |
| Total Debt | $15.0M +50.2% | $10.0M -40.5% | $16.7M +3.3% | $16.2M +8.0% | $15.0M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$6.0M -115.3% | -$2.8M -334.2% | $1.2M +113.9% | -$8.5M +69.6% | -$28.0M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.29B
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$485.30M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$346.38M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$344.52M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$266.50M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$223.26M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$217.64M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$211.33M
Immuneering Corporation
NASDAQ:IMRX
$156.64M
Humacyte, Inc.
NASDAQ:HUMA
$154.02M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does ACHV have?
Achieve Life Sciences, Inc. (ACHV) reported $20.93M in cash and equivalents in fiscal 2025.
How much debt does ACHV carry?
Achieve Life Sciences, Inc. (ACHV) reported $14.96M of total debt, with net debt of -$5,974,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.